295 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
INCY: BMO Capital Markets starts at Market Perform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20190913142141 Sep 13, 2019 - BMO Capital Markets issues rating change for INCY
INCY: BMO Capital Markets starts at Market Perform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20190911190500 Sep 11, 2019 - BMO Capital Markets issues rating change for INCY
Merck's Keytruda Combination Gets EC Nod for Kidney Cancer http://www.zacks.com/stock/news/503040/mercks-keytruda-combination-gets-ec-nod-for-kidney-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503040 Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
INCY: Oppenheimer ups to Outperform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20190905063824 Sep 05, 2019 - Oppenheimer issues rating change for INCY
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I http://www.zacks.com/stock/news/429331/concert-pharmas-ctp-692-positive-for-schizophrenia-in-phase-i?cid=CS-ZC-FT-429331 Jun 13, 2019 - Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/428338/mercks-keytruda-wins-fda-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-428338 Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Incyte Begins Phase III Study for Treatment of Duct Cancer http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-ZC-FT-425849 Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Celgene (CELG) Presents Data on Pipeline Candidates at ASCO http://www.zacks.com/stock/news/424905/celgene-celg-presents-data-on-pipeline-candidates-at-asco?cid=CS-ZC-FT-424905 Jun 05, 2019 - Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.
Novartis (NVS) Announces Various Data Presentations at ASCO http://www.zacks.com/stock/news/424089/novartis-nvs-announces-various-data-presentations-at-asco?cid=CS-ZC-FT-424089 Jun 03, 2019 - Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
Mesoblast Starts Rolling BLA Submission for Remestemcel-L http://www.zacks.com/stock/news/422489/mesoblast-starts-rolling-bla-submission-for-remestemcel-l?cid=CS-ZC-FT-422489 May 30, 2019 - Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.

Pages: 12345678910...30

<<<Page 5>